Arnauld C Verschuur
Overview
Explore the profile of Arnauld C Verschuur including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
237
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Welter N, Al-Saadi R, Gravier-Dumonceau R, Furtwangler R, Graf N, Wegert J, et al.
Pediatr Blood Cancer
. 2025 Feb;
72(4):e31580.
PMID: 39895484
Background: Recent research elucidated the prognostic significance of molecular biology in Wilms tumor (WT) by linking somatic genomic variants (such as gain of chromosome 1q) to unfavorable patient outcomes. This...
2.
Sprokkerieft J, van der Beek J, Spreafico F, Selle B, Chowdhury T, Graf N, et al.
Crit Rev Oncol Hematol
. 2024 Sep;
204:104523.
PMID: 39326645
Renal cell carcinoma (RCC) is a very rare type of renal cancer in children and young adults. When metastasized or recurrent, no standards of care are available, and outcome is...
3.
Sprokkerieft J, van der Beek J, Spreafico F, Selle B, Thebaud E, Chowdhury T, et al.
Cancer Med
. 2024 Aug;
13(1):e6782.
PMID: 39102694
Introduction: Introduction: Renal cell carcinoma (RCC) is a very rare pediatric renal tumor. Robust evidence to guide treatment is lacking and knowledge on targeted therapies and immunotherapy is mainly based...
4.
Casanova M, Bautista F, Campbell-Hewson Q, Makin G, Marshall L, Verschuur A, et al.
Clin Cancer Res
. 2023 Aug;
29(21):4341-4351.
PMID: 37606641
Purpose: This phase Ib study defined the safety, MTD, and recommended phase II dose (RP2D) of regorafenib combined with vincristine and irinotecan (VI). Secondary objectives were evaluation of antitumor activity...
5.
Groenendijk A, van Tinteren H, Jiang Y, de Krijger R, Vujanic G, Godzinski J, et al.
Eur J Cancer
. 2022 Jan;
163:88-97.
PMID: 35042071
Purpose: Society of International Pediatric Oncology - Renal Tumor Study Group (SIOP-RTSG) treatment recommendations for relapsed Wilms tumour (WT) are stratified by the intensity of first-line treatment. To explore the...
6.
Wang E, Dubois S, Wetmore C, Verschuur A, Khosravan R
Eur J Drug Metab Pharmacokinet
. 2021 Apr;
46(3):343-352.
PMID: 33852135
Background And Objective: Population pharmacokinetic analysis explored the pharmacokinetics of sunitinib and its primary active metabolite, SU012662, in children and evaluated the sunitinib dose(s) that produce comparable plasma exposures to...
7.
Davila Fajardo R, Furtwangler R, van Grotel M, van Tinteren H, Pasqualini C, Pritchard-Jones K, et al.
Cancers (Basel)
. 2021 Mar;
13(5).
PMID: 33652659
Objective: Wilms tumour (WT) patients with a localised completely necrotic nephroblastoma after preoperative chemotherapy are a favourable outcome group. Since the introduction of the SIOP 2001 protocol, the SIOP- Renal...
8.
van der Beek J, Geller J, de Krijger R, Graf N, Pritchard-Jones K, Drost J, et al.
Cancers (Basel)
. 2020 Jul;
12(7).
PMID: 32635225
Pediatric renal cell carcinoma (RCC) is a rare type of kidney cancer, most commonly occurring in teenagers and young adolescents. Few relatively large series of pediatric RCC have been reported....
9.
Pasqualini C, Furtwangler R, van Tinteren H, Teixeira R, Acha T, Howell L, et al.
Eur J Cancer
. 2020 Feb;
128:38-46.
PMID: 32109849
Introduction: High-risk (HR) metastatic (stage IV) Wilms tumours (WTs) have a particular poor outcome. Methods: Here, we report the results of HR (diffuse anaplastic [DA] or blastemal type [BT]) stage...
10.
Verschuur A, Bajciova V, Mascarenhas L, Khosravan R, Lin X, Ingrosso A, et al.
Cancer Chemother Pharmacol
. 2019 Apr;
84(1):41-50.
PMID: 31006038
Background: Sunitinib is approved for treatment of adults with imatinib-resistant gastrointestinal stromal tumor (GIST) or imatinib intolerance. Methods: This single-arm, multicenter, multinational phase I/II clinical trial (NCT01396148) enrolled eligible patients...